ABBOTT LABORATORIES Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$311.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-04-29
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$311.00M, a 163.60% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $683.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$108.00M, a 132.63% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $841.00M, a 2612.90% increase year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $1.91B.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$67.00M, a 131.60% decline from fiscal 2023.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $212.00M, a 34.37% decline from fiscal 2022.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $323.00M, a 43.53% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$311.00M 10-Q · filed 2026-04-29 | $372.00M derived: sum of 2 quarters · filed 2026-04-29 | $264.00M derived: sum of 3 quarters · filed 2026-04-29 | $1.10B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $683.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $575.00M derived: sum of 2 quarters · filed 2026-02-20 | $1.42B derived: sum of 3 quarters · filed 2026-02-20 | $1.91B 10-K · filed 2026-02-20 |
| 2025-09-30 | -$108.00M 10-Q · filed 2025-10-29 | $733.00M derived: sum of 2 quarters · filed 2025-10-29 | $1.22B 10-Q · filed 2025-10-29 | $1.12B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $841.00M 10-Q · filed 2025-07-30 | $1.33B 10-Q · filed 2025-07-30 | $1.23B derived: sum of 3 quarters · filed 2026-04-29 | $1.56B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $489.00M 10-Q · filed 2026-04-29 | $387.00M derived: sum of 2 quarters · filed 2026-04-29 | $718.00M derived: sum of 3 quarters · filed 2026-04-29 | $749.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$102.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $229.00M derived: sum of 2 quarters · filed 2026-02-20 | $260.00M derived: sum of 3 quarters · filed 2026-02-20 | -$67.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $331.00M 10-Q · filed 2025-10-29 | $362.00M derived: sum of 2 quarters · filed 2025-10-29 | $35.00M 10-Q · filed 2025-10-29 | $676.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $31.00M 10-Q · filed 2025-07-30 | -$296.00M 10-Q · filed 2025-07-30 | $345.00M derived: sum of 3 quarters · filed 2026-02-20 | -$64.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | -$327.00M 10-Q · filed 2025-04-30 | $314.00M derived: sum of 2 quarters · filed 2026-02-20 | -$95.00M derived: sum of 3 quarters · filed 2026-02-20 | -$127.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $641.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $232.00M derived: sum of 2 quarters · filed 2026-02-20 | $200.00M derived: sum of 3 quarters · filed 2026-02-20 | $212.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$409.00M 10-Q · filed 2024-10-31 | -$441.00M derived: sum of 2 quarters · filed 2024-10-31 | -$429.00M 10-Q · filed 2024-10-31 | $965.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$32.00M 10-Q · filed 2024-07-31 | -$20.00M 10-Q · filed 2024-07-31 | $1.37B derived: sum of 3 quarters · filed 2025-02-21 | $635.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $12.00M 10-Q · filed 2024-05-02 | $1.41B derived: sum of 2 quarters · filed 2025-02-21 | $667.00M derived: sum of 3 quarters · filed 2025-02-21 | $435.00M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $1.39B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $655.00M derived: sum of 2 quarters · filed 2025-02-21 | $423.00M derived: sum of 3 quarters · filed 2025-02-21 | $323.00M 10-K · filed 2025-02-21 |
| 2022-09-30 | -$739.00M 10-Q · filed 2023-11-01 | -$971.00M derived: sum of 2 quarters · filed 2023-11-01 | -$1.07B 10-Q · filed 2023-11-01 | -$205.00M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | -$232.00M 10-Q · filed 2023-08-03 | -$332.00M 10-Q · filed 2023-08-03 | $534.00M derived: sum of 3 quarters · filed 2024-02-16 | $360.00M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | -$100.00M 10-Q · filed 2023-05-04 | $766.00M derived: sum of 2 quarters · filed 2024-02-16 | $592.00M derived: sum of 3 quarters · filed 2024-02-16 | $811.00M derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | $866.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $692.00M derived: sum of 2 quarters · filed 2024-02-16 | $911.00M derived: sum of 3 quarters · filed 2024-02-16 | $572.00M 10-K · filed 2024-02-16 |
| 2021-09-30 | -$174.00M 10-Q · filed 2022-11-01 | $45.00M derived: sum of 2 quarters · filed 2022-11-01 | -$294.00M 10-Q · filed 2022-11-01 | -$196.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $219.00M 10-Q · filed 2022-08-02 | -$120.00M 10-Q · filed 2022-08-02 | -$22.00M derived: sum of 3 quarters · filed 2023-02-17 | $14.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$339.00M 10-Q · filed 2022-05-03 | -$241.00M derived: sum of 2 quarters · filed 2023-02-17 | -$205.00M derived: sum of 3 quarters · filed 2023-02-17 | $101.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $98.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $134.00M derived: sum of 2 quarters · filed 2023-02-17 | $440.00M derived: sum of 3 quarters · filed 2023-02-17 | -$481.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $36.00M 10-Q · filed 2021-11-03 | $342.00M derived: sum of 2 quarters · filed 2021-11-03 | -$579.00M 10-Q · filed 2021-11-03 | -$1.28B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $306.00M 10-Q · filed 2021-08-04 | -$615.00M 10-Q · filed 2021-08-04 | -$1.32B derived: sum of 3 quarters · filed 2022-02-18 | -$1.72B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | -$921.00M 10-Q · filed 2021-05-05 | -$1.62B derived: sum of 2 quarters · filed 2022-02-18 | -$2.02B derived: sum of 3 quarters · filed 2022-02-18 | -$1.92B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | -$702.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$1.10B derived: sum of 2 quarters · filed 2022-02-18 | -$995.00M derived: sum of 3 quarters · filed 2022-02-18 | -$879.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | -$398.00M 10-Q · filed 2020-11-04 | -$293.00M derived: sum of 2 quarters · filed 2020-11-04 | -$177.00M 10-Q · filed 2020-11-04 | -$417.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $105.00M 10-Q · filed 2020-07-29 | $221.00M 10-Q · filed 2020-07-29 | -$19.00M derived: sum of 3 quarters · filed 2021-02-19 | -$115.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $116.00M 10-Q · filed 2020-04-29 | -$124.00M derived: sum of 2 quarters · filed 2021-02-19 | -$220.00M derived: sum of 3 quarters · filed 2021-02-19 | -$1.40B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | -$240.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$336.00M derived: sum of 2 quarters · filed 2021-02-19 | -$1.52B derived: sum of 3 quarters · filed 2021-02-19 | -$1.19B 10-K · filed 2021-02-19 |
| 2018-09-30 | -$96.00M 10-Q · filed 2019-10-31 | -$1.28B derived: sum of 2 quarters · filed 2019-10-31 | -$952.00M 10-Q · filed 2019-10-31 | -$898.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | -$1.18B 10-Q · filed 2019-07-31 | -$856.00M 10-Q · filed 2019-07-31 | -$802.00M derived: sum of 3 quarters · filed 2020-02-21 | -$668.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $324.00M 10-Q · filed 2019-05-01 | $378.00M derived: sum of 2 quarters · filed 2020-02-21 | $512.00M derived: sum of 3 quarters · filed 2020-02-21 | $794.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $188.00M derived: sum of 2 quarters · filed 2020-02-21 | $470.00M derived: sum of 3 quarters · filed 2020-02-21 | $1.05B 10-K · filed 2020-02-21 |
| 2017-09-30 | $134.00M 10-Q · filed 2018-10-31 | $416.00M derived: sum of 2 quarters · filed 2018-10-31 | $998.00M 10-Q · filed 2018-10-31 | $268.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $282.00M 10-Q · filed 2018-08-01 | $864.00M 10-Q · filed 2018-08-01 | $134.00M derived: sum of 3 quarters · filed 2019-02-22 | $824.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | $582.00M 10-Q · filed 2018-05-02 | -$148.00M derived: sum of 2 quarters · filed 2019-02-22 | $542.00M derived: sum of 3 quarters · filed 2019-02-22 | $170.00M derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | -$730.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$40.00M derived: sum of 2 quarters · filed 2019-02-22 | -$412.00M derived: sum of 3 quarters · filed 2019-02-22 | -$605.00M 10-K · filed 2019-02-22 |
| 2016-09-30 | $690.00M 10-Q · filed 2017-11-02 | $318.00M derived: sum of 2 quarters · filed 2017-11-02 | $125.00M 10-Q · filed 2017-11-02 | $678.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$372.00M 10-Q · filed 2017-08-02 | -$565.00M 10-Q · filed 2017-08-02 | -$12.00M derived: sum of 3 quarters · filed 2018-02-16 | -$2.22B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$193.00M 10-Q · filed 2017-05-03 | $360.00M derived: sum of 2 quarters · filed 2018-02-16 | -$1.85B derived: sum of 3 quarters · filed 2018-02-16 | -$1.24B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $553.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$1.65B derived: sum of 2 quarters · filed 2018-02-16 | -$1.05B derived: sum of 3 quarters · filed 2018-02-16 | -$1.73B 10-K · filed 2018-02-16 |
| 2015-09-30 | -$2.21B 10-Q · filed 2016-11-03 | -$1.60B derived: sum of 2 quarters · filed 2016-11-03 | -$2.29B 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $603.00M 10-Q · filed 2016-08-03 | -$78.00M 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | -$681.00M 10-Q · filed 2016-05-04 | |||
| 2014-12-31 | -$3.04B 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $572.00M 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |